Lisata Therapeutics, Inc.
LSTA
NASDAQ·Healthcare·Biotechnology·Mkt cap $15.0M
$1.65
▲ +0.61%
P/E
-1.01
Mkt Cap
$15.0M
52-Wk Range
$0.99–$5.07
52-Week Range
$0.99 - $5.07
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 24.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- SAKIGAKE designation for HONEDRA providing expedited regulatory pathway
- Proprietary CD34+ cell therapy technology platform
- Advanced clinical trial progress across multiple indications
- Experienced leadership with deep biopharmaceutical expertise
Bear Case
1 risk
- Low volatility (beta 0.8).
Growth
Moderate growth ahead
Clinical trial progression toward regulatory approval milestones
Value
Deep value opportunity - significant discount to sector peers
Momentum
Falling
-50.8% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying LSTA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Most recent quarter reported revenue of $0. Reported EPS of -$0.32.
Reported EPS · last 4Q
0 of 1 beats
Q3 26
—
Revenue trend · last 8Q
—
—
—
—
—
-90%
—
-100%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$1.0M
$0
$70.0K
$0
$100.0K
$0
$0
Margins · last 8Q
Gross
—
Profit
—
Wall Street consensus
1 analyst · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
100%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · May 15, 2026
vs Industry
How LSTA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.